Arca
Skip to content
Tools
Tools

ERBB4: Receptor tyrosine-protein kinase erbB-4

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis.

  • Drugs that act on it: 7
  • Approved: 3
  • In phases 1 to 3: 4
  • Sponsors: 6

Who Is On It, and How Far Along

Every drug ChEMBL records acting on ERBB4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved3

  • Neratinib
  • Afatinib
  • Dacomitinib anhydrous

Phase 31

  • Canertinib

Phase 21

  • BMS-690514

Phase 12

  • AC-480
  • JNJ-26483327

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule7100%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Receptor protein-tyrosine kinase erbB-4 inhibitor.
NeratinibApprovedPuma BiotechnologySmall moleculeInhibitor—33—
AfatinibApprovedArriVent BioPharma, Inc.Small moleculeInhibitor—28—
Dacomitinib anhydrousApprovedPfizerSmall moleculeInhibitor—0—
CanertinibPhase 3PfizerSmall moleculeInhibitor—0—
BMS-690514Phase 2Bristol-Myers SquibbSmall moleculeInhibitor—0—
AC-480Phase 1Daiichi SankyoSmall moleculeInhibitor—0—
JNJ-26483327Phase 1Johnson & JohnsonSmall moleculeInhibitor—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNeratinibPhase 2Not yet recruitingUniversity of California, San Diego2026-07-27
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerAfatinibPhase 2 / Phase 3Not yet recruitingPeking University Cancer Hospital & Institute2026-06-17
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNeratinibPhase 2Not yet recruitingXijing Hospital2026-01-12
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsAfatinibPhase 3RecruitingArriVent BioPharma, Inc.2025-09-22
RT for Adenocarcinoma/Adenosquamous CarcinomaNeratinibPhase 1 / Phase 2Active, not recruitingPeking Union Medical College Hospital2025-09-04
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisNeratinibPhase 2RecruitingFudan University2025-09-03
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World StudyNeratinib—Not yet recruitingHebei Medical University Fourth Hospital2025-06-13
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaAfatinibPhase 1 / Phase 2Active, not recruitingWest China Hospital2025-06-08
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer PatientsNeratinibNot applicableRecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2025-03-24
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted TherapyNeratinibEarly phase 1RecruitingVanderbilt-Ingram Cancer Center2025-02-14
Using Tumor Models to Determine TreatmentsNeratinibPhase 2RecruitingUniversity Health Network, Toronto2025-02-06
FHND9041 Versus Afatinib for Non-small Cell Lung CancerAfatinibPhase 3Enrolling by invitationJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.2025-01-06
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaAfatinibPhase 1 / Phase 2RecruitingWest China Hospital2024-12-31
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLCAfatinibPhase 2RecruitingShandong Public Health Clinical Center2024-11-29
Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)AfatinibPhase 1 / Phase 2RecruitingFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau2024-10-18
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyAfatinibPhase 3RecruitingRegion Skane2024-07-03

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Non-small cell lung carcinoma
0.68
Neoplasm
0.61
Cancer
0.61
Abnormality of the skeletal system
0.55
Medullary thyroid gland carcinoma
0.55
Hereditary disease
0.51
Breast carcinoma
0.49
Lung adenocarcinoma
0.49

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
ERBB4

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3009, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q15303, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.